Epcoritamab Clinical Trials (2026): 52 Studies for Follicular Lymphoma & Diffuse Large B-Cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
52 Epcoritamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 34 indications (including Follicular Lymphoma & Diffuse Large B-Cell Lymphoma) and 7,475 total planned enrollment. 6 Phase 3 Epcoritamab trials and 30 Phase 2 are listed. 31 Epcoritamab clinical trials are actively recruiting at 111 U.S. sites across 33 states. Most recent activity: NCT06191744 (Nov 2037).
Where to Participate: All Epcoritamab Trial Sites in the U.S. (111 sites across 33 states)
Every actively recruiting Epcoritamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope Medical Center | Duarte91010 | NCT07218510 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07365306 | Map |
| CA | UCSF Fresno /ID# 264712 | Fresno93701-2302 | NCT06191744 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT07218510 | Map |
| CA | City of Hope at Long Beach Elm | Long Beach90813 | NCT07218510 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06905509 | Map |
| CA | Scripps Mercy Hospital /ID# 265393 | San Diego92103 | NCT06191744 | Map |
| CA | Sansum Clinic Research /ID# 261596 | Santa Barbara93105 | NCT06191744 | Map |
| CA | Stanford | Stanford94305 | NCT06510361 | Map |
| CO | Rocky Mountain Cancer Centers - Boulder /ID# 261203 | Boulder80303 | NCT06191744 | Map |
| CT | Yale University School of Medicine /ID# 242089 | New Haven06510 | NCT05283720 | Map |
| DE | Christiana Care Health Service /ID# 242301 | Newark19713 | NCT05283720 | Map |
| DE | Christiana Care Health Service /ID# 261207 | Newark19713 | NCT06191744 | Map |
| FL | Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 | Jacksonville32256 | NCT06191744 | Map |
| FL | University of Miami | Miami33136 | NCT06796998 | Map |
| FL | University of Miami | Miami33136 | NCT06919939 | Map |
| FL | Advent Health /ID# 261578 | Orlando32803 | NCT06191744 | Map |
| FL | Orlando Health Cancer Institute /ID# 260983 | Orlando32806 | NCT06191744 | Map |
| FL | Moffitt Cancer Center /ID# 259487 | Tampa33612-9416 | NCT06191744 | Map |
| FL | Tampa General Hospital /ID# 246748 | Tampa33606 | NCT05283720 | Map |
| GA | City of Hope Atlanta Cancer Center | Newnan30265 | NCT07218510 | Map |
| ID | Beacon Cancer Care - Coeur d'Alene /ID# 260670 | Coeur d'Alene83814 | NCT06191744 | Map |
| IL | Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 | Chicago60611 | NCT06191744 | Map |
| IL | Cancer Care Specialists Of Central Illinois /ID# 272464 | Decatur62526 | NCT06191744 | Map |
| IL | Illinois Cancer Care, PC /ID# 261526 | Peoria61615 | NCT06191744 | Map |
| IN | Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 | Fort Wayne46804 | NCT06191744 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT05852717 | Map |
| IA | University of Iowa Health Care /ID# 262132 | Des Moines50314-3017 | NCT06191744 | Map |
| KY | Norton Cancer Institute - St. Matthews /ID# 261076 | Louisville40207 | NCT06191744 | Map |
| KY | University of Louisville Hospital /ID# 260544 | Louisville40202 | NCT06191744 | Map |
| ME | New England Cancer Specialists - Westbrook /ID# 260672 | Westbrook04092 | NCT06191744 | Map |
| MD | University of Maryland, Baltimore /ID# 242218 | Baltimore21201 | NCT05283720 | Map |
| MD | University of Maryland, Baltimore /ID# 259538 | Baltimore21201 | NCT06191744 | Map |
| MD | Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 | Bethesda20817 | NCT06191744 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05783609 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06510361 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06510491 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05783609 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06510491 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06563596 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06811272 | Map |
| MA | Newton-Wellesley Hospital | Newton02462 | NCT06811272 | Map |
| MI | Karmanos Cancer Center (Wayne State University) | Detroit48201 | NCT05852717 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06536049 | Map |
| MO | St. Luke's Hospital - Chesterfield /ID# 260489 | Chesterfield63017 | NCT06191744 | Map |
| MO | Washington University | St Louis63110 | NCT06672705 | Map |
| MT | Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 | Billings59102 | NCT06191744 | Map |
| NE | Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 | Grand Island68803 | NCT06191744 | Map |
| NE | NHO - Nebraska Hematology-Oncology /ID# 269692 | Lincoln68506 | NCT06191744 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505 | Omaha68130 | NCT06191744 | Map |
| NE | University of Nebraska Medical Center /ID# 261996 | Omaha68198 | NCT06191744 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT07082868 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT07082868 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT07082868 | Map |
| NM | Presbyterian Kaseman Hospital /ID# 262451 | Albuquerque87110 | NCT06191744 | Map |
| NM | University of New Mexico /ID# 261083 | Albuquerque87102-4517 | NCT06191744 | Map |
| NM | Presbyterian Rust Medical Center /ID# 262447 | Rio Rancho87124 | NCT06191744 | Map |
| NY | Memorial Sloan Kettering Commack (Limited Protocol Activities) | Commack11725 | NCT07082868 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT07082868 | Map |
| NY | Northwell Health - Monter Cancer Center /ID# 245435 | Lake Success11042 | NCT05283720 | Map |
| NY | NYU Langone Hospital - Long Island /ID# 265531 | Mineola11501 | NCT06191744 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06510361 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 242123 | New York10029 | NCT05283720 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 259595 | New York10029 | NCT06191744 | Map |
| NY | Icahn School of Medicine at Mount Sinai Hospital | New York10029 | NCT05783609 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT06563596 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07082868 | Map |
| NY | NYU Langone Medical Center /ID# 264518 | New York10016-6402 | NCT06191744 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT05783609 | Map |
| NY | New York Oncology Hematology /ID# 270208 | Troy12180 | NCT06191744 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT07082868 | Map |
| NY | Clinical Research Alliance - Westbury /ID# 261078 | Westbury11590 | NCT06191744 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06510491 | Map |
| NC | Novant Health Presbyterian Medical Center /ID# 259740 | Charlotte28204 | NCT06191744 | Map |
| NC | East Carolina University - Brody School of Medicine /ID# 242506 | Greenville27834 | NCT05283720 | Map |
| NC | Novant Health Forsyth Medical Center /ID# 259741 | Winston-Salem27103 | NCT06191744 | Map |
| OH | Oncology Hematology Care, Inc - Blue Ash /ID# 261204 | Cincinnati45252 | NCT06191744 | Map |
| OH | University of Cincinnati | Cincinnati45219 | NCT07108998 | Map |
| OH | Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland44195 | NCT06447376 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06536049 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06672705 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT05783609 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT06563596 | Map |
| OR | Oncology Associates of Oregon, P.C. /ID# 261816 | Eugene97401 | NCT06191744 | Map |
| PA | Abramson Cancer Center at the University of Pennsylvania | Philadelphia19104 | NCT06458439 | Map |
| SC | MUSC Hollings Cancer Center /ID# 259604 | Charleston29425 | NCT06191744 | Map |
| SC | Prisma Health /ID# 259602 | Greenville29605 | NCT06191744 | Map |
| TN | Sarah Cannon Research Institute - Tristar Centennial Medical Center /ID# 274985 | Nashville37203 | NCT06191744 | Map |
| TX | Texas Oncology - Austin Midtown /ID# 261208 | Austin78705 | NCT06191744 | Map |
| TX | Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206 | Dallas75246-2003 | NCT06191744 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT05852717 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06045247 | Map |
| TX | MD Anderson Cancer Center /ID# 260984 | Houston77030-4000 | NCT06191744 | Map |
| TX | Oncology Consultants /ID# 268390 | Houston77030 | NCT06191744 | Map |
| TX | Joe Arrington Cancer Research /ID# 260382 | Lubbock79410 | NCT06191744 | Map |
| UT | Huntsman Cancer Institute at University of Utah | Salt Lake City84112 | NCT07528352 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06238648 | Map |
| UT | Intermountain Healthcare LDS Hospital /ID# 259759 | Salt Lake City84143 | NCT06191744 | Map |
| UT | University of Utah (Data Collection Only) | Salt Lake City84112 | NCT07082868 | Map |
| VA | University of Virginia Health System | Charlottesville22908 | NCT05852717 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 261205 | Fairfax22031 | NCT06191744 | Map |
| VA | Oncology and Hematology Associates of Southwest Virginia /ID# 261592 | Roanoke98684 | NCT06191744 | Map |
| WA | Swedish Cancer Institute - Edmonds /ID# 266356 | Edmonds98026 | NCT06191744 | Map |
| WA | Swedish Cancer Institute - Issaquah /ID# 266358 | Issaquah98029 | NCT06191744 | Map |
| WA | Vista Oncology - East Olympia /ID# 261360 | Olympia98506-5028 | NCT06191744 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07097363 | Map |
| WA | Swedish Medical Center - Seattle /ID# 242269 | Seattle98104 | NCT05283720 | Map |
| WA | Swedish Medical Center - Seattle /ID# 260370 | Seattle98104 | NCT06191744 | Map |
| WA | Virginia Mason Hospital & Medical Center /ID# 260549 | Seattle98101 | NCT06191744 | Map |
| WA | Northwest Medical Specialties - Tacoma /ID# 262133 | Tacoma98405 | NCT06191744 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05783609 | Map |
Epcoritamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | terminated | withdrawn | suspended | not yet recruiting | no longer available | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 4 | 2 | 6 | ||||||
| P1/P2 | 2 | 5 | 1 | 8 | |||||
| P2 | 23 | 4 | 1 | 1 | 1 | 30 | |||
| P3 | 1 | 5 | 6 | ||||||
| N/A | 1 | 1 | 2 |
Recruiting Epcoritamab clinical trials (31)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06191744 | EPCORE™FL-2Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | P3 | Follicular Lymphoma (FL) | 1,095 | Feb 2024 |
| NCT05791409 | AETHERVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | P1/P2 | CLL/SLL | 112 | Apr 2024 |
| NCT05283720 | SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | Non-Hodgkin Lymphoma | 496 | Jun 2022 |
| NCT07126236 | REPIFIRResponse-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | P2 | Large B Cell Lymphoma | 80 | Aug 2025 |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 39 | Dec 2023 |
| NCT05848765 | REFRACTRelapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | P2 | Relapsed Follicular Lymphoma | 284 | Sep 2023 |
| NCT07528352 | REBELExternal Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | P1 | Diffuse Large B Cell Lymphoma | 12 | Jun 2026 |
| NCT06796998 | MZLEpcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | P2 | Marginal Zone Lymphoma | 25 | Oct 2025 |
| NCT06919939 | EPCOR+LONCAEpcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | P2 | Large B-cell Lymphoma | 26 | Jan 2026 |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | P2 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 120 | Jan 2024 |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | P2 | Recurrent Diffuse Large B-Cell Lymphoma | 25 | Jul 2025 |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | Large B-cell Lymphoma | 40 | Jan 2024 |
| NCT07097363 | EPOCH-REpcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | P2 | B-Cell Non-Hodgkin Lymphoma | 18 | Dec 2025 |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | P2 | Follicular Lymphoma | 45 | Jan 2025 |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | P2 | Follicular Lymphoma | 100 | Jun 2023 |
| NCT06931652 | E-REVRIStudy of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab | P2 | Primary CNS Lymphoma (PCNSL) | 60 | Sep 2025 |
| NCT07197307 | CLEARCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | P2 | Aggressive Diffuse Large B-cell Lymphoma | 120 | Oct 2025 |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 43 | Apr 2026 |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | P2 | CLL/SLL | 22 | Aug 2025 |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | P2 | Chronic Lymphocytic Leukemia | 33 | Jan 2026 |
| NCT05852717 | GDPSafety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | P2 | Large Cell Lymphoma, Diffuse | 32 | Oct 2023 |
| NCT06811272 | Outpatient Epcoritamab as 2L in NTE R/R DLBCL | P2 | Relapsed Large B-cell Lymphoma | 30 | Jun 2025 |
| NCT06447376 | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | P1 | Non-Hodgkin Lymphoma | 20 | Jan 2025 |
| NCT07082868 | CNSLA Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | P1 | Primary Central Nervous System Lymphoma (PCNSL) | 26 | Aug 2025 |
| NCT06414148 | EpLCARTMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma | P2 | Relapsed/Refractory Large B-cell Lymphoma | 40 | May 2024 |
| NCT06510361 | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy | P2 | Lymphoma | 35 | Nov 2024 |
| NCT06510491 | Epcoritamab in Previously Treated WM | P2 | Waldenstrom Macroglobulinemia | 20 | Dec 2024 |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | P2 | Lymphoma, Non-Hodgkin | 31 | Sep 2024 |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | P1/P2 | Recurrent Diffuse Large B-Cell Lymphoma | 38 | Apr 2025 |
| NCT07451652 | Low Dose Epcoritamab Plus GemOx in R/R DLBCL | P2 | Relapsed/Refractory Diffuse Large B Cell Lymphoma | 10 | Mar 2026 |
| NCT06672705 | Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | P1 | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder | 26 | Jun 2025 |
Epcoritamab clinical trials by indication
Diffuse Large B-Cell Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05578976 | EPCORE DLBCL-2 | P3 | active not recruiting | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT07226752 | — | P3 | active not recruiting | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China |
| NCT06508658 | EPCORE DLBCL-4 | P3 | active not recruiting | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT04663347 | EPCORE™ NHL-2 | P1/P2 | active not recruiting | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) |
| NCT05451810 | SC | P2 | active not recruiting | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma |
| NCT05660967 | EPCORE DLBCL-3 | P2 | active not recruiting | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma |
Large B-cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06919939 | EPCOR+LONCA | P2 | recruiting | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma |
| NCT06045247 | — | P2 | recruiting | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma |
| NCT05733650 | — | N/A | approved for marketing | Expanded Access Program for Epcoritamab |
Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06510361 | — | P2 | recruiting | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy |
| NCT07030699 | ECLAT | P2 | withdrawn | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma |
| NCT05692050 | — | N/A | no longer available | Expanded Access to Epcoritamab |
Follicular Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06563596 | — | P2 | recruiting | Epco, Zanu, Ritux for R/R FL or MZL |
| NCT05783609 | — | P2 | recruiting | Epcoritamab and Rituximab for First-line Follicular Lymphoma |
| NCT06112847 | — | P2 | active not recruiting | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma |
Diffuse Large B Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07528352 | REBEL | P1 | recruiting | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL |
| NCT04542824 | EPCORE™ NHL-3 | P1/P2 | active not recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) |
B-Cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07097363 | EPOCH-R | P2 | recruiting | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma |
| NCT05201248 | SC | P1/P2 | active not recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma |
CLL/SLL (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05791409 | AETHER | P1/P2 | recruiting | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL |
| NCT07108998 | — | P2 | recruiting | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL |
Recurrent Diffuse Large B-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06905509 | — | P2 | recruiting | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma |
| NCT06536049 | — | P1/P2 | recruiting | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma |
Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05283720 | SC | P2 | recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma |
| NCT06447376 | — | P1 | recruiting | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab |
Follicular Lymphoma (FL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06191744 | EPCORE™FL-2 | P3 | recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT05409066 | EPCORE FL-1 | P3 | active not recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
Diffuse Large B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04628494 | EPCORE DLBCL-1 | P3 | active not recruiting | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT04358458 | FIH | P1/P2 | terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas |
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07365306 | — | P2 | recruiting | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Relapsed/Refractory Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07451652 | — | P2 | recruiting | Low Dose Epcoritamab Plus GemOx in R/R DLBCL |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07218510 | — | P2 | recruiting | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial |
Aggressive Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07197307 | CLEAR | P2 | not yet recruiting | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
Marginal Zone Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06796998 | MZL | P2 | recruiting | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) |
Primary CNS Lymphoma (PCNSL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06931652 | E-REVRI | P2 | recruiting | Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab |
Primary Central Nervous System Lymphoma (PCNSL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07082868 | CNSL | P1 | recruiting | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) |
Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07126236 | REPIFIR | P2 | recruiting | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma |
Recurrent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06723457 | — | P2 | active not recruiting | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma |
Leukemia, Chronic Lymphocytic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06676033 | — | P1 | active not recruiting | Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome |
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06672705 | — | P1 | recruiting | Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders |
Relapsed Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06811272 | — | P2 | recruiting | Outpatient Epcoritamab as 2L in NTE R/R DLBCL |
Recurrent Grade 1 Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06575686 | — | P2 | suspended | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma |
Waldenstrom Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06510491 | — | P2 | recruiting | Epcoritamab in Previously Treated WM |
Lymphoma, Non-Hodgkin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06458439 | — | P2 | recruiting | Epcoritamab-CAR T Cells for Large B-cell Lymphomas |
Relapsed/Refractory Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06414148 | EpLCART | P2 | recruiting | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma |
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06238648 | — | P2 | recruiting | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy |
DLBCL - Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06287398 | — | P2 | recruiting | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL |
Large Cell Lymphoma, Diffuse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05852717 | GDP | P2 | recruiting | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma |
Relapsed Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05848765 | REFRACT | P2 | recruiting | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy |
Non-hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05206357 | SC | P1 | active not recruiting | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab |
Relapsed/Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04623541 | EPCORE™ CLL-1 | P1/P2 | active not recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome |
DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03625037 | EPCORE™ NHL-1 | P1/P2 | active not recruiting | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
Epcoritamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| EPCORE™FL-2 | NCT06191744 | P3 | recruiting | Follicular Lymphoma (FL) | 1,095 | — |
| EPCORE DLBCL-2 | NCT05578976 | P3 | active not recruiting | Diffuse Large B-Cell Lymphoma | 900 | — |
| EPCORE FL-1 | NCT05409066 | P3 | active not recruiting | Follicular Lymphoma (FL) | 549 | — |
| EPCORE DLBCL-1 | NCT04628494 | P3 | active not recruiting | Diffuse Large B-cell Lymphoma | 483 | — |
| EPCORE DLBCL-4 | NCT06508658 | P3 | active not recruiting | Diffuse Large B-Cell Lymphoma | 379 | — |
| SC | NCT05283720 | P2 | recruiting | Non-Hodgkin Lymphoma | 496 | — |
| REPIFIR | NCT07126236 | P2 | recruiting | Large B Cell Lymphoma | 80 | — |
| REFRACT | NCT05848765 | P2 | recruiting | Relapsed Follicular Lymphoma | 284 | — |
| MZL | NCT06796998 | P2 | recruiting | Marginal Zone Lymphoma | 25 | — |
| EPCOR+LONCA | NCT06919939 | P2 | recruiting | Large B-cell Lymphoma | 26 | — |
| EPOCH-R | NCT07097363 | P2 | recruiting | B-Cell Non-Hodgkin Lymphoma | 18 | — |
| E-REVRI | NCT06931652 | P2 | recruiting | Primary CNS Lymphoma (PCNSL) | 60 | — |
| CLEAR | NCT07197307 | P2 | not yet recruiting | Aggressive Diffuse Large B-cell Lymphoma | 120 | — |
| GDP | NCT05852717 | P2 | recruiting | Large Cell Lymphoma, Diffuse | 32 | — |
| EpLCART | NCT06414148 | P2 | recruiting | Relapsed/Refractory Large B-cell Lymphoma | 40 | — |
| SC | NCT05451810 | P2 | active not recruiting | Diffuse Large B-Cell Lymphoma | 184 | — |
| EPCORE DLBCL-3 | NCT05660967 | P2 | active not recruiting | Diffuse Large B-Cell Lymphoma | 111 | — |
| ECLAT | NCT07030699 | P2 | withdrawn | Lymphoma | 0 | — |
Terminated and withdrawn Epcoritamab trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06575686suspendedEpcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- NCT07030699withdrawnA Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
- NCT04358458terminatedFirst-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
All Epcoritamab trials (52)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06191744 | EPCORE™FL-2 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | P3 | recruiting | 1,095 | Genmab | Feb 2024 |
| NCT05791409 | AETHER | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | P1/P2 | recruiting | 112 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Apr 2024 |
| NCT05283720 | SC | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | recruiting | 496 | Genmab | Jun 2022 |
| NCT07126236 | REPIFIR | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | P2 | recruiting | 80 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Aug 2025 |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | P2 | recruiting | 39 | Australasian Leukaemia and Lymphoma Group | Dec 2023 | |
| NCT05848765 | REFRACT | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | P2 | recruiting | 284 | University of Birmingham | Sep 2023 |
| NCT07528352 | REBEL | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | P1 | recruiting | 12 | University of Utah | Jun 2026 |
| NCT06796998 | MZL | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | P2 | recruiting | 25 | Izidore Lossos, MD | Oct 2025 |
| NCT06919939 | EPCOR+LONCA | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | P2 | recruiting | 26 | University of Miami | Jan 2026 |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | P2 | recruiting | 120 | Academic and Community Cancer Research United | Jan 2024 | |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | P2 | recruiting | 25 | Joseph Tuscano | Jul 2025 | |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | recruiting | 40 | M.D. Anderson Cancer Center | Jan 2024 | |
| NCT07097363 | EPOCH-R | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | P2 | recruiting | 18 | University of Washington | Dec 2025 |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | P2 | recruiting | 45 | Reid Merryman, MD | Jan 2025 | |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | P2 | recruiting | 100 | Reid Merryman, MD | Jun 2023 | |
| NCT06931652 | E-REVRI | Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab | P2 | recruiting | 60 | The Lymphoma Academic Research Organisation | Sep 2025 |
| NCT07197307 | CLEAR | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | P2 | not yet recruiting | 120 | Universität Münster | Oct 2025 |
| NCT05578976 | EPCORE DLBCL-2 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | P3 | active not recruiting | 900 | Genmab | Feb 2023 |
| NCT05409066 | EPCORE FL-1 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | P3 | active not recruiting | 549 | Genmab | Sep 2022 |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | recruiting | 43 | City of Hope Medical Center | Apr 2026 | |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | P2 | recruiting | 22 | Zulfa Omer | Aug 2025 | |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | P2 | recruiting | 33 | City of Hope Medical Center | Jan 2026 | |
| NCT06723457 | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | P2 | active not recruiting | 34 | Northwestern University | Jul 2025 | |
| NCT03625037 | EPCORE™ NHL-1 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | P1/P2 | active not recruiting | 666 | Genmab | Jun 2018 |
| NCT05206357 | SC | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | P1 | active not recruiting | 17 | Genmab | Oct 2022 |
| NCT05852717 | GDP | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | P2 | recruiting | 32 | Dipenkumar Modi | Oct 2023 |
| NCT06811272 | Outpatient Epcoritamab as 2L in NTE R/R DLBCL | P2 | recruiting | 30 | Massachusetts General Hospital | Jun 2025 | |
| NCT06447376 | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | P1 | recruiting | 20 | Taylor Brooks | Jan 2025 | |
| NCT07082868 | CNSL | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | P1 | recruiting | 26 | Memorial Sloan Kettering Cancer Center | Aug 2025 |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | P2 | suspended | 33 | City of Hope Medical Center | Mar 2025 | |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | P3 | active not recruiting | 72 | Genmab | Oct 2022 | |
| NCT06414148 | EpLCART | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma | P2 | recruiting | 40 | Peter MacCallum Cancer Centre, Australia | May 2024 |
| NCT06510361 | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy | P2 | recruiting | 35 | Beth Israel Deaconess Medical Center | Nov 2024 | |
| NCT04628494 | EPCORE DLBCL-1 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | P3 | active not recruiting | 483 | Genmab | Jan 2021 |
| NCT06508658 | EPCORE DLBCL-4 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P3 | active not recruiting | 379 | Genmab | Aug 2024 |
| NCT04623541 | EPCORE™ CLL-1 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | P1/P2 | active not recruiting | 194 | Genmab | Nov 2020 |
| NCT06510491 | Epcoritamab in Previously Treated WM | P2 | recruiting | 20 | Gottfried von Keudell, MD PhD | Dec 2024 | |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | P2 | recruiting | 31 | Abramson Cancer Center at Penn Medicine | Sep 2024 | |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | P1/P2 | recruiting | 38 | Yazeed Sawalha | Apr 2025 | |
| NCT07451652 | Low Dose Epcoritamab Plus GemOx in R/R DLBCL | P2 | recruiting | 10 | Hospital Universitario Dr. Jose E. Gonzalez | Mar 2026 | |
| NCT04663347 | EPCORE™ NHL-2 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | P1/P2 | active not recruiting | 543 | Genmab | Nov 2020 |
| NCT04542824 | EPCORE™ NHL-3 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | P1/P2 | active not recruiting | 78 | Genmab | Aug 2020 |
| NCT06676033 | Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome | P1 | active not recruiting | 5 | National Heart, Lung, and Blood Institute (NHLBI) | Jul 2025 | |
| NCT05451810 | SC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | P2 | active not recruiting | 184 | Genmab | Aug 2022 |
| NCT06672705 | Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | P1 | recruiting | 26 | Timothy Voorhees | Jun 2025 | |
| NCT06112847 | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | P2 | active not recruiting | 29 | City of Hope Medical Center | Jan 2024 | |
| NCT05660967 | EPCORE DLBCL-3 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 111 | Genmab | Mar 2023 |
| NCT07030699 | ECLAT | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma | P2 | withdrawn | 0 | Memorial Sloan Kettering Cancer Center | Aug 2025 |
| NCT05201248 | SC | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 49 | Genmab | Mar 2022 |
| NCT04358458 | FIH | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | P1/P2 | terminated | 46 | Genmab | Mar 2020 |
| NCT05733650 | Expanded Access Program for Epcoritamab | — | approved for marketing | 0 | Genmab | — | |
| NCT05692050 | Expanded Access to Epcoritamab | — | no longer available | 0 | AbbVie | — |
Epcoritamab clinical trials: frequently asked questions
- How many Epcoritamab clinical trials are there?
- 52 Epcoritamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 30 are actively recruiting participants.
- Are Epcoritamab clinical trials recruiting in 2026?
- Yes — 30 Epcoritamab trials are actively recruiting in 2026, with 111 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Epcoritamab being studied for?
- Epcoritamab is being studied for Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Small Lymphocytic Lymphoma, High-grade B-cell Lymphoma, Lymphoma and 125 more. The trials are grouped by indication on this page.
- What phase is Epcoritamab in?
- Epcoritamab clinical trials span 6 Phase 3, 30 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Epcoritamab clinical trials?
- The lead sponsor across the most Epcoritamab trials is Genmab, with 30 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Epcoritamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: